Regenerative Medical Technologies Group Increases Q1 2025 Sales By 67% Over Q1 2024 and Achieves Operating Profit for the Quarter of $134,000
Regenerative Medical Technologies Group (RMTG) reported strong Q1 2025 financial results, with sales exceeding $1.35 million, marking a 67% increase compared to Q1 2024. The company achieved an operational profit of $134,000 for the quarter.
RMTG has introduced a new revenue stream through Turnkey exclusive memberships, where members pay upfront fees for assistance in setting up regenerative medical clinics, including training and support. Members are required to purchase supplies exclusively from RMTG. The company plans to onboard one new member per quarter initially, with plans to significantly increase this rate next year.
Management expects continued revenue growth across all four business lines and sustained increases in operating income, with official guidance for the remainder of 2025 and the next two years to be announced soon.
Regenerative Medical Technologies Group (RMTG) ha riportato risultati finanziari solidi nel primo trimestre del 2025, con vendite superiori a 1,35 milioni di dollari, registrando un incremento del 67% rispetto al primo trimestre del 2024. L'azienda ha ottenuto un profitto operativo di 134.000 dollari nel trimestre.
RMTG ha introdotto una nuova fonte di guadagno grazie alle iscrizioni esclusive Turnkey, in cui i membri pagano una quota anticipata per ricevere assistenza nell'apertura di cliniche di medicina rigenerativa, comprensiva di formazione e supporto. I membri devono acquistare forniture esclusivamente da RMTG. L'azienda prevede di acquisire un nuovo membro per trimestre inizialmente, con l'obiettivo di aumentare significativamente questo ritmo nel prossimo anno.
La direzione prevede una crescita continua dei ricavi in tutte e quattro le linee di business e un aumento costante dell'utile operativo, con le linee guida ufficiali per il resto del 2025 e per i prossimi due anni che saranno annunciate a breve.
Regenerative Medical Technologies Group (RMTG) reportó sólidos resultados financieros en el primer trimestre de 2025, con ventas que superaron los 1,35 millones de dólares, lo que representa un incremento del 67% en comparación con el primer trimestre de 2024. La compañía logró una ganancia operativa de 134,000 dólares durante el trimestre.
RMTG ha lanzado una nueva fuente de ingresos mediante membresías exclusivas Turnkey, donde los miembros pagan una tarifa inicial para recibir asistencia en la creación de clínicas de medicina regenerativa, incluyendo capacitación y soporte. Los miembros deben adquirir suministros exclusivamente de RMTG. La empresa planea incorporar un nuevo miembro por trimestre inicialmente, con planes de aumentar significativamente esta tasa el próximo año.
La dirección espera un crecimiento continuo de los ingresos en las cuatro líneas de negocio y aumentos sostenidos en los ingresos operativos, con una guía oficial para el resto de 2025 y los próximos dos años que será anunciada pronto.
Regenerative Medical Technologies Group (RMTG)는 2025년 1분기에 강력한 재무 성과를 보고했으며, 매출은 135만 달러를 넘어 2024년 1분기 대비 67% 증가했습니다. 회사는 해당 분기에 13만 4천 달러의 영업 이익을 달성했습니다.
RMTG는 Turnkey 독점 멤버십을 통한 새로운 수익원을 도입했으며, 회원들은 재생 의료 클리닉 설립을 위한 지원, 교육 및 지원을 받기 위해 선불 요금을 지불합니다. 회원들은 RMTG에서만 공급품을 구매해야 합니다. 회사는 초기에는 분기당 한 명의 신규 회원을 유치할 계획이며, 내년에는 이 비율을 크게 늘릴 예정입니다.
경영진은 네 개 사업 부문 모두에서 지속적인 매출 성장을 기대하며, 영업 이익도 꾸준히 증가할 것으로 전망하고 있습니다. 2025년 나머지 기간과 향후 2년간의 공식 가이던스는 곧 발표될 예정입니다.
Regenerative Medical Technologies Group (RMTG) a annoncé de solides résultats financiers pour le premier trimestre 2025, avec des ventes dépassant 1,35 million de dollars, soit une augmentation de 67% par rapport au premier trimestre 2024. L'entreprise a réalisé un bénéfice opérationnel de 134 000 dollars sur la période.
RMTG a lancé une nouvelle source de revenus grâce aux adhésions exclusives Turnkey, où les membres paient des frais initiaux pour bénéficier d'une assistance dans la création de cliniques de médecine régénérative, incluant formation et support. Les membres doivent acheter leurs fournitures exclusivement auprès de RMTG. La société prévoit d'intégrer un nouveau membre par trimestre dans un premier temps, avec l'intention d'augmenter significativement ce rythme l'année prochaine.
La direction prévoit une croissance continue du chiffre d'affaires dans les quatre secteurs d'activité et une augmentation soutenue des résultats opérationnels, avec des prévisions officielles pour le reste de 2025 et les deux années suivantes qui seront annoncées prochainement.
Regenerative Medical Technologies Group (RMTG) meldete starke Finanzergebnisse für das erste Quartal 2025, mit Umsätzen von über 1,35 Millionen US-Dollar, was einem 67%igen Anstieg gegenüber dem ersten Quartal 2024 entspricht. Das Unternehmen erzielte im Quartal einen operativen Gewinn von 134.000 US-Dollar.
RMTG hat eine neue Einnahmequelle durch exklusive Turnkey-Mitgliedschaften eingeführt, bei denen Mitglieder Vorauszahlungen leisten, um Unterstützung bei der Einrichtung regenerativer medizinischer Kliniken, einschließlich Schulungen und Support, zu erhalten. Mitglieder sind verpflichtet, Materialien ausschließlich von RMTG zu beziehen. Das Unternehmen plant zunächst, pro Quartal ein neues Mitglied aufzunehmen, mit der Absicht, diese Rate im nächsten Jahr deutlich zu erhöhen.
Das Management erwartet weiterhin Umsatzwachstum in allen vier Geschäftsbereichen und anhaltende Steigerungen des operativen Ergebnisses. Offizielle Prognosen für den Rest des Jahres 2025 und die folgenden zwei Jahre werden bald bekannt gegeben.
- 67% year-over-year sales growth to $1.35M in Q1 2025
- Achieved operational profit of $134,000 in Q1 2025
- Launched new revenue stream through Turnkey exclusive memberships
- Secured recurring revenue through exclusive supply agreements with members
- Limited initial scaling of new membership program (only one new member per quarter)
- Dependency on exclusive supply agreements may limit market expansion
Regenerative Medical Technologies Group, Inc. $RMTG, a regenerative medicine company, is pleased to announce that sales for its first quarter of 2025 surpassed
LAS VEGAS, NV / ACCESS Newswire / May 21, 2025 / Regenerative Medical Technologies Group, Inc. (the "Company" or "RMTG"), a regenerative medicine company is pleased to announce that sales for its first quarter of 2025 surpassed
As sales continue to increase and the overall industry continues to gain momentum, the Company has introduced a new revenue stream. The Company has commenced selling Turnkey exclusive memberships, where new members pay a fee upfront in exchange for turnkey assistance in setting up a regenerative medical clinic in their area along with continuous training and support. The members are bound to purchase all supplies exclusively from RMTG. RMTG expects to onboard one new member per quarter for now and expects to increase this rate of onboarding significantly as of next year.
"We are extremely pleased with this quarter's performance and continuing our significant trend of positive operating income. We expect to see continued revenue growth in our four lines of business and sustained increases in operating income," said David Christensen CEO/President of the Company.
The Company expects to issue official guidance on revenues for the remainder of this year and for the next 2 years in a subsequent press release in the near future.
This press release should be read in conjunction with all of the company's filings on www.sec.gov
About Regenerative Medical Technologies Group, Inc.
Regenerative Medical Technologies Group, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Regenerative Medical Technologies Group, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Regenerative Medical Technologies Group, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact: investor.relations@regenmedtechgroup.com
SOURCE: Regenerative Medical Technology Group
View the original press release on ACCESS Newswire
FAQ
What was RMTG's revenue growth in Q1 2025?
How much operational profit did RMTG report in Q1 2025?
What is RMTG's new Turnkey membership program?
How many new Turnkey members does RMTG plan to onboard?
What are RMTG's future growth expectations?
